Prostate Cancer : Cancer And Cancer

For example, age is the biggest factor. We all know that as men age and get older they run a higher chance of their prostate enlarging and developing cancer. Family history and race are also the other two big ones. If people in your immediate family have had the cancer, then you run a higher risk of contraction because you’re already genetically predisposed to getting prostate cancer. Also, African American men are more likely to be diagnosed with the cancer, with white and Hispanic men following behind. According to the CDC, from the years 1999-2013, black men had higher mortality and contraction rates than men of other races and ethnicities.1 Hormones are also a risk factor; should the male be producing a lot of testosterone could put him at risk.

The ACS guidelines also recommend screening men who are at high risk as early as 40 years of age (black, relative that was diagnosed young, Braca 1 (breast cancer) 1 or Braca 2. However, the USPSTF advises against PCa screening concluding there is moderate certainty that the benefits of such screening do not outweigh the harms (Quaseem et al., 2013).

There are multiple methods for screening for Prostate Cancer; the most common is Digital Rectal Examination. During a digital rectal exam a doctor inserts a glove, lubricated finger into the rectum to feel for any irregular or abnormal firm area in the prostate gland.

Each year approximately 233,000 men will be diagnosed with prostate cancer (Eggener, Cifu, & Nabhan, 2015). In 2015, prostate cancer was the second most common cancer related cause of death among United States men (Eggener, et. al., 2015). While the majority of prostate cancers are slow growing with a 5-year survival rate of approximately 98%, statistics show that when prostate cancer is identified as metastatic, the 5-year survival rate dramatically drops down to 20-25% (Eggener, et. al., 2015). According to these numbers alone, it appears screening for prostate cancer would be a well-accepted practice. However, current methods of screening for this cancer are controversial and has lead organizations like the U.S Preventative Service Task Force (USPSTF) and the American Cancer Society (ACS) to different guidelines for screening.

A cancer cell is formed when the cell’s DNA is damaged but not repaired. Instead of the cell dying, like a normal cell, it reproduces new cells which also have the damaged DNA that the original cell had. Factors that can cause a cell to be damaged are mistakes during the reproduction of the cell, environmental reasons, such as smoking or too much sun exposure. The cancer cells form tumors which then invade the tissue of a certain body part, like the breast, lungs, brain, or prostate. Cancer can spread sometimes from body part to body part, but is named from where it starts. For instance, if somebody were to be diagnosed with breast cancer, and developed cancer in their lungs, it would be metastatic lung cancer. Metastasis is how cancer can spread to other body

Prostate cancer originates in the male prostate gland. Cancers in this gland are the most common malignancies, which grow very slowly, and can have minimal effect on a man’s quality of life. However, a tumor in the prostate gland can be problematic for men, especially black men, even though it is only about the size of a walnut. Located below the bladder and in front of the rectum, the prostate provides the fluid that nourishes and protects sperm cells in the semen. Researchers are still debating the cause of this disease, although certain risk factors such as age, ethnicity, culture, environment, diet, and family history, increase the chance of getting it. Prostate cancer affects African American men and early screening and detection are the key factors that can be used to prevent mortality and reduce morbidity, especially in the Brooklyn area.

Prostate cancer is a kind of cancer that affects the prostate gland in men. It is a common cancer that grows slowly and its treatment can be done successfully if it is detected at an early stage. Sometimes, symptoms are not visible in case of cancer limited to the prostate gland which may result into metastatic cancer. To detect the symptoms, active surveillance can be done. There are various options available

A prostate is a gland in the male reproductive system found below the bladder and in front of the rectum. Prostate cancer is cancer that forms in tissue in that gland, it usually occurs in older men. Cancer comes in forms of tumors, which is an abnormal growth of cells. Malignant tumors are the cancerous tumors of the two different types of tumors. Can cause pain and interfere with normal function, but they can also cause other systems in the body to act abnormally. Malignant tumors can invade nearby groups of cells or tissues, crowding out and destroying normal cells.

There are several different types of cancers in the world, including testicular cancer. Testicular cancer is a disease only found in males where uncontrolled growth of abnormal cells are found in the tesicles that is commonly seen in young men from the ages of 15 to 35. Although it is one of the most curable types of cancer, there are different types of testicular cancer where there are several cells that start in a different part of the tesitcles that can cause the development of one or more types of cancer. Testicals are the male sex glands which produce testosterone, hormones, and also make and store sperm. Tesicles, often reffered to as testes, are found behind the penis inside the scrotum, they are about the size of a golf ball, which usually make up one portion of the male reproductive system.

The prostate is a walnut sized shaped gland surrounding the top of the urethra whose growth and function is controlled by hormones such-as testosterone. A normal prostate in adult men has a mean weight of about 11g. The function of the prostate is to produce a majority of seminal fluid (Marker et al. 2003).

TREATMENT of localized prostate cancer usually includes prostatectomy and radiation therapy, occasionally augmented with hormonal therapies. However, Fu et al., (2012) have noted that recurrence of prostate cancer occurs in about 15% of patients within 5 years after prostatectomy and in about 40% patients within 10 years. Although, more than 70% of patients are expected to survive for more than 10 years after prostatectomy, radiation or hormone therapy, Cooperberg et al.,(2010) argued that localized prostate cancer patients with intermediate or high risk scores have higher mortality rate after these treatments. With chemotherapies as the existing treatment options for metastatic prostate cancers, patients are expected to have only a median survival of 12-15 months. Bono et al.,(2006). However, most of these traditional treatments are invasive and riddled with adverse side effects. Therefore, novel therapies are on high demand for the treatment of the malignant and recurrent forms of prostate cancer after these

Prostatic carcinoma is more common in older men after age 50, however any man is at risk for this type of cancer. American Society of Clinical Oncology says that more than 80% of prostate cancers are diagnosed in men who are 65 or older.

According to Ferrante, Shaw, and Scott (2011), prostate cancer is the most common cancer and second most common cancer death among men in the United States. Early detection permits appropriate and timely management, which can allow clinicians to treat the cancer effectively. When detected at early or regional stage, prostate cancer has a five-year survival rate of about 100%. Prostate-specific antigen (PSA) is the most widely used tumor marker and was approved by the FDA in 1994 as an aid in the early detection of prostate cancer (Duffy, 2011). PSA screening helps detect prostate cancer earlier, at lower clinical stages, and with a lower Gleason score (Cho et al., 2015).

Sexual dysfunction represents a prevalent long-term complication among prostate cancer survivors with a wide spectrum of manifestations and a huge impact on quality of life [4]. Resnick et al (2013) reported long-term effects of sexual function after radical prostate cancer treatment reported by prostate cancer survivors. As shown in a 15-yr follow-up study consisted of 1655 men who had localized prostate cancer the decline in erectile function following treatment is progressive, regardless of treatment type (eg, surgery, radiation therapy). (20)

Prostate cancer is the second most common cancer and it is the second leading cause of cancer death in American men according to the American Cancer Society(ACS) ( 2016). Older age is the strongest risk factor for the development of prostate cancer. Approximately 1 in 7 men will be diagnosed with prostate cancer during his lifetime (ACS, 2016). There are more than 2.9 million prostate cancer survivors in the United States (ACS, 2016). The risk of dying from prostate cancer is 2.9 percent, with seventy percent of deaths occurring after age 75(ACS, 2016; Howlader, Krapcho, Neyman,Aminou et al, 2011). The use of the prostate-specific antigen testing transformed prostate cancer screening in the 1990’s (Up to date) . PSA screening for prostate